An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma

CC BY-NC-ND 4.0 · South Asian J Cancer 2019; 08(03): 159-165
DOI: 10.4103/sajc.sajc_18_19

Letter to the Editor

Autor*innen

Vikas T. Talreja

Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, Indiai
Vanita Noronha

Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, Indiai
Amit Joshi

Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, Indiai
Vijay Patil

Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, Indiai
Abhishek Mahajan

Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, Indiai
Kumar Prabhash

Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, Indiai

References
1 Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T, et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 2011;89:716-24, 724A-724C.
2 Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, et al. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Cancer 2008;112:1555-61.
3 Quispel-Janssen J. OA13.01 a phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): With translational research (TR) biopies. J Thoracic Oncol 2017;12:S292-3.
4 Available from: https://www.eortc.be/services/doc/ctc/CTCAE_4.032010-06-14_QuickReference_5x7.pdf. [Last accessed on 2018 Dec 12].